Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
A Multi-Center, Open-Label, Multiple Administration, Rising Dose Study of the Safety, Tolerability, and Efficacy of IL-12 Gene Medicine in Patients With Unresectable or Recurrent/Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  4/19/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
A Multi-Center, Open-Label, Multiple Administration, Rising Dose Study of the Safety, Tolerability, and Efficacy of IL-12 Gene Medicine in Patients With Unresectable or Recurrent/Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 4/19/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial
Cancer Prevention and Treatment Among African American Older Adults
Status: Enrolling
Updated:  4/19/2017
Bloomberg School of Public Health
mi
from
Baltimore, MD
Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial
Cancer Prevention and Treatment Among African American Older Adults
Status: Enrolling
Updated: 4/19/2017
Bloomberg School of Public Health
mi
from
Baltimore, MD
Click here to add this to my saved trials
Experimental Device to Improve Colonoscopy
A Trial of Segmental Stiffening Wires to Improve the Efficiency and Patient Tolerability of Colonoscopy
Status: Enrolling
Updated:  4/20/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Experimental Device to Improve Colonoscopy
A Trial of Segmental Stiffening Wires to Improve the Efficiency and Patient Tolerability of Colonoscopy
Status: Enrolling
Updated: 4/20/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission
The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL).
Status: Enrolling
Updated:  4/20/2017
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Nashville, TN
Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission
The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL).
Status: Enrolling
Updated: 4/20/2017
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Nashville, TN
Click here to add this to my saved trials
Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission
The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL).
Status: Enrolling
Updated:  4/20/2017
Vanderbilt-Ingram Cancer Center at Franklin
mi
from
Nashville, TN
Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission
The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL).
Status: Enrolling
Updated: 4/20/2017
Vanderbilt-Ingram Cancer Center at Franklin
mi
from
Nashville, TN
Click here to add this to my saved trials
Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission
The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL).
Status: Enrolling
Updated:  4/20/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission
The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL).
Status: Enrolling
Updated: 4/20/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
A Pilot/ Phase 2 Study of Pentostatin Plus Cyclophosphamide Immune Depletion to Decrease Immunogenicity of SS1P in Patients With Mesothelioma, Lung Cancer or Pancreatic Cancer
Status: Enrolling
Updated:  4/20/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
A Pilot/ Phase 2 Study of Pentostatin Plus Cyclophosphamide Immune Depletion to Decrease Immunogenicity of SS1P in Patients With Mesothelioma, Lung Cancer or Pancreatic Cancer
Status: Enrolling
Updated: 4/20/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated:  4/20/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated: 4/20/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated:  4/20/2017
Winthrop University Hospital
mi
from
Mineola, NY
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated: 4/20/2017
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated:  4/20/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated: 4/20/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated:  4/20/2017
Oregon Health and Science University
mi
from
Portland, OR
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated: 4/20/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated:  4/20/2017
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated: 4/20/2017
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated:  4/20/2017
Queen Elizabeth II Health Sciences Centre
mi
from
Halifax,
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated: 4/20/2017
Queen Elizabeth II Health Sciences Centre
mi
from
Halifax,
Click here to add this to my saved trials
Study of ABT-700 in Subjects With Advanced Solid Tumors
A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/20/2017
Scottsdale Healthcare Research Institute /ID# 64046
mi
from
Scottsdale, AZ
Study of ABT-700 in Subjects With Advanced Solid Tumors
A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/20/2017
Scottsdale Healthcare Research Institute /ID# 64046
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of ABT-700 in Subjects With Advanced Solid Tumors
A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/20/2017
University of Chicago Medical Center /ID# 66110
mi
from
Chicago, IL
Study of ABT-700 in Subjects With Advanced Solid Tumors
A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/20/2017
University of Chicago Medical Center /ID# 66110
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of ABT-700 in Subjects With Advanced Solid Tumors
A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/20/2017
Wayne State University /ID# 57555
mi
from
Detroit, MI
Study of ABT-700 in Subjects With Advanced Solid Tumors
A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/20/2017
Wayne State University /ID# 57555
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of ABT-700 in Subjects With Advanced Solid Tumors
A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/20/2017
Duke Cancer Institute /ID# 66111
mi
from
Durham, NC
Study of ABT-700 in Subjects With Advanced Solid Tumors
A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/20/2017
Duke Cancer Institute /ID# 66111
mi
from
Durham, NC
Click here to add this to my saved trials
Study of ABT-700 in Subjects With Advanced Solid Tumors
A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/20/2017
Fox Chase Cancer Center /ID# 103795
mi
from
Philadelphia, PA
Study of ABT-700 in Subjects With Advanced Solid Tumors
A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/20/2017
Fox Chase Cancer Center /ID# 103795
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of ABT-700 in Subjects With Advanced Solid Tumors
A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/20/2017
Asan Medical Center /ID# 75774
mi
from
Seoul,
Study of ABT-700 in Subjects With Advanced Solid Tumors
A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/20/2017
Asan Medical Center /ID# 75774
mi
from
Seoul,
Click here to add this to my saved trials
Faith Moves Mountains: An Appalachian Cervical Cancer Prevention Project
An Appalachian Cervical Cancer Prevention Project
Status: Enrolling
Updated:  4/20/2017
Faith Moves Mountains
mi
from
Whitesburg, KY
Faith Moves Mountains: An Appalachian Cervical Cancer Prevention Project
An Appalachian Cervical Cancer Prevention Project
Status: Enrolling
Updated: 4/20/2017
Faith Moves Mountains
mi
from
Whitesburg, KY
Click here to add this to my saved trials
Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors
A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors
Status: Enrolling
Updated:  4/24/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors
A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors
Status: Enrolling
Updated: 4/24/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors
A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors
Status: Enrolling
Updated:  4/24/2017
Cleveland Medical Center, University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors
A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors
Status: Enrolling
Updated: 4/24/2017
Cleveland Medical Center, University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes
A Multi-center, An Open Label, Dose-Escalation Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment for Myelodysplastic Syndromes
Status: Enrolling
Updated:  4/24/2017
Rush-Presbyterian-St. Luke's Medical Center
mi
from
Chicago, IL
Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes
A Multi-center, An Open Label, Dose-Escalation Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment for Myelodysplastic Syndromes
Status: Enrolling
Updated: 4/24/2017
Rush-Presbyterian-St. Luke's Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated:  4/24/2017
Stanford University
mi
from
Palo Alto, CA
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated: 4/24/2017
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated:  4/24/2017
Rady Children's Hospital
mi
from
San Diego, CA
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated: 4/24/2017
Rady Children's Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated:  4/24/2017
Peyton Manning Children's Hospital at St. Vincent
mi
from
Indianapolis, IN
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated: 4/24/2017
Peyton Manning Children's Hospital at St. Vincent
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated:  4/24/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated: 4/24/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated:  4/24/2017
Children's Hospital of Michigan
mi
from
Detroit, MI
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated: 4/24/2017
Children's Hospital of Michigan
mi
from
Detroit, MI
Click here to add this to my saved trials
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated:  4/24/2017
Columbia University Medical Center
mi
from
New York, NY
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated: 4/24/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated:  4/24/2017
Rhode Island Hospital
mi
from
Providence, RI
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated: 4/24/2017
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated:  4/24/2017
St.Jude Children's Research Hospital
mi
from
Memphis, TN
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated: 4/24/2017
St.Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated:  4/24/2017
Cook Children's Medical Center
mi
from
Fort Worth, TX
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated: 4/24/2017
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated:  4/24/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated: 4/24/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated:  4/24/2017
Mid-West Children's Cancer Center
mi
from
Milwaukee, WI
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Status: Enrolling
Updated: 4/24/2017
Mid-West Children's Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase I Study of Dalteparin, A Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multi-targeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  4/25/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase I Study of Dalteparin, A Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multi-targeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 4/25/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase I Study of Dalteparin, A Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multi-targeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  4/25/2017
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase I Study of Dalteparin, A Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multi-targeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 4/25/2017
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase I Study of Dalteparin, A Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multi-targeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  4/25/2017
Academ Zienkenhuis Bij De University
mi
from
Amsterdam,
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase I Study of Dalteparin, A Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multi-targeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 4/25/2017
Academ Zienkenhuis Bij De University
mi
from
Amsterdam,
Click here to add this to my saved trials
Patient Preferences for Breast Reconstruction After Mastectomy
Patient Preferences for Breast Reconstruction After Mastectomy
Status: Enrolling
Updated:  4/25/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Patient Preferences for Breast Reconstruction After Mastectomy
Patient Preferences for Breast Reconstruction After Mastectomy
Status: Enrolling
Updated: 4/25/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies
Status: Enrolling
Updated:  4/25/2017
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies
Status: Enrolling
Updated: 4/25/2017
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies
Status: Enrolling
Updated:  4/25/2017
Georgia Regents University- Cancer Center
mi
from
Augusta, GA
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies
Status: Enrolling
Updated: 4/25/2017
Georgia Regents University- Cancer Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies
Status: Enrolling
Updated:  4/25/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies
Status: Enrolling
Updated: 4/25/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies
Status: Enrolling
Updated:  4/25/2017
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies
Status: Enrolling
Updated: 4/25/2017
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies
Status: Enrolling
Updated:  4/25/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies
Status: Enrolling
Updated: 4/25/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
EUS-FNA of Solid Pancreatic Mass Lesions Using a Novel Corkscrew Technique: a Pilot Study
EUS-guided Fine Needle Tissue Acquisition of Solid Pancreatic Mass Lesions Using a Novel Corkscrew Technique: a Pilot Study
Status: Enrolling
Updated:  4/25/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
EUS-FNA of Solid Pancreatic Mass Lesions Using a Novel Corkscrew Technique: a Pilot Study
EUS-guided Fine Needle Tissue Acquisition of Solid Pancreatic Mass Lesions Using a Novel Corkscrew Technique: a Pilot Study
Status: Enrolling
Updated: 4/25/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Integrating Palliative Care Into Self-Management of Breast Cancer
Integrating Palliative Care Into Self-Management of Breast Cancer
Status: Enrolling
Updated:  4/25/2017
Yale-New Haven Hospital
mi
from
New Haven, CT
Integrating Palliative Care Into Self-Management of Breast Cancer
Integrating Palliative Care Into Self-Management of Breast Cancer
Status: Enrolling
Updated: 4/25/2017
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Integrating Palliative Care Into Self-Management of Breast Cancer
Integrating Palliative Care Into Self-Management of Breast Cancer
Status: Enrolling
Updated:  4/25/2017
Yale School of Nursing
mi
from
West Haven, CT
Integrating Palliative Care Into Self-Management of Breast Cancer
Integrating Palliative Care Into Self-Management of Breast Cancer
Status: Enrolling
Updated: 4/25/2017
Yale School of Nursing
mi
from
West Haven, CT
Click here to add this to my saved trials
Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer
A Phase II Trial of Hyperthermia and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate
Status: Enrolling
Updated:  4/25/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer
A Phase II Trial of Hyperthermia and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate
Status: Enrolling
Updated: 4/25/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
A Phase II Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/25/2017
Abraxis BioScience, Inc.
mi
from
Durham, NC
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
A Phase II Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/25/2017
Abraxis BioScience, Inc.
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms.
Status: Enrolling
Updated:  4/27/2017
Excel Diagnostic Imaging Clinics
mi
from
Houston, TX
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms.
Status: Enrolling
Updated: 4/27/2017
Excel Diagnostic Imaging Clinics
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms.
Status: Enrolling
Updated:  4/27/2017
St. Luke's Episcopal Hospital
mi
from
Houston, TX
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms.
Status: Enrolling
Updated: 4/27/2017
St. Luke's Episcopal Hospital
mi
from
Houston, TX
Click here to add this to my saved trials